1. Membrane Transporter/Ion Channel
  2. Potassium Channel
  3. SKA-31

SKA-31 

Cat. No.: HY-111655
Handling Instructions

SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure.

For research use only. We do not sell to patients.

SKA-31 Chemical Structure

SKA-31 Chemical Structure

CAS No. : 40172-65-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 77 In-stock
Estimated Time of Arrival: December 31
5 mg USD 70 In-stock
Estimated Time of Arrival: December 31
10 mg USD 100 In-stock
Estimated Time of Arrival: December 31
50 mg USD 390 In-stock
Estimated Time of Arrival: December 31
100 mg USD 690 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure[1].

IC50 & Target

EC50: 2.9 μM (KCa2.1), 1.9 μM (KCa2.2), 2.9 μM (KCa2.3), 260 nM (KCa3.1)[1]

In Vitro

SKA-31 activates KCa2/3 Channels more potently than Riluzole, and is more selective over other Ion channels[1].
SKA-31 reduces cell viability with IC50s of 5.3 μM , 46.9 μM in HCT-116 cells and HCT-8 cells, respectively[2].
SKA-31 (5.3 μM; 0-96 hours) reduces HCT-116 cells proliferation when added at time zero at 5.3 μM[2].
SKA-31 triggers apoptosis in HCT-116 cells at 5 μM, and the effect is smaller in HCT-8 cells at 45 μM[2].
SKA-31 increases the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines at 5 μM and 45 μM, respectively[2].
SKA-31 further activates Caspase 3 and reduces Akt phosphorylation induced by Cisplatin[2].
SKA-31 has a synergic effect with Cisplatin also on the inhibition of HCT-116 cell proliferation[2].

Cell Viability Assay[2]

Cell Line: HCT-116 cells, HCT-8 cells
Concentration:
Incubation Time: 24 hours
Result: Reduced cell viability with IC50s of 5.3 μM , 46.9 μm in HCT-116 and HCT-8, respectively.

Cell Proliferation Assay[2]

Cell Line: HCT-116 cells
Concentration: 5.3 μM
Incubation Time: 0-96 hours
Result: Reduced HCT-116 cells proliferation when added at time zero at IC50S value.

Apoptosis Analysis[2]

Cell Line: HCT-116 cells, HCT-8 cells
Concentration: 5 μM (HCT-116 cells), 45 μM (HCT-8 cells)
Incubation Time: 24 hours
Result: Triggered apoptosis in HCT-116 cells, and the effect was smaller in HCT-8 cells.

Cell Cycle Analysis[2]

Cell Line: HCT-116cells, HCT-8 cells
Concentration: 5 μM (HCT-116), 45 μM (HCT-8)
Incubation Time: 24 hours
Result: Increased the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines.

Western Blot Analysis[2]

Cell Line: HCT-116 cells
Concentration:
Incubation Time: 24 hours
Result: Further activated Caspase 3 and reduced Akt phosphorylation when co-treatment with Cisplatin in HCT-116 cells.
In Vivo

SKA-31 Is not acutely toxic and has good pharmacokinetic properties[1].
SKA-31 potentiates native KCa3.1 and KCa2.3 in murine carotid endothelium with EC50 values of 225 nM and 1.6 μM for KCa3.1 and KCa2.3, respectively[1].
SKA-31 stimulates KCa3.1 and KCa2.3 in vascular endothelial cells and increases acetylcholine-induced endothelium-derived hyperpolarizing factor (EDHF) -mediated vasodilation[1].
SKA-31 potentiates EDHF-type vasodilations and lowers blood pressure in mice. Injections of SKA-31 (1-30 mg/kg; i.p.) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-)[1].

Animal Model: 16-25 weeks mice[1]
Dosage: 1 mg/kg, 10 mg/kg, and 30 mg/kg
Administration: Intraperitoneal injection
Result: Lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-).
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
References
Molecular Weight

200.26

Formula

C₁₁H₈N₂S

CAS No.

40172-65-4

SMILES

NC1=NC2=C3C=CC=CC3=CC=C2S1

Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SKA-31
Cat. No.:
HY-111655
Quantity:

SKA-31

Cat. No.: HY-111655